EXEL - Exelixis, Inc. Common Stock -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Exelixis, Inc. Common Stock
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date: May 1, 2000
Sector: Healthcare
Industry: Biotech
Market Cap: $14.62B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.32 | 2.45%
Avg Daily Range (30 D): $0.82 | 1.43%
Avg Daily Range (90 D): $0.92 | 1.68%
Institutional Daily Volume
Avg Daily Volume: 2.07M
Avg Daily Volume (30 D): 1.49M
Avg Daily Volume (90 D): 1.66M
Trade Size
Avg Trade Size (Sh.): 149
Avg Trade Size (Sh.) (30 D): 55
Avg Trade Size (Sh.) (90 D): 56
Institutional Trades
Total Institutional Trades: 13,381
Avg Institutional Trade: $3.28M
Avg Institutional Trade (30 D): $6.46M
Avg Institutional Trade (90 D): $7.92M
Avg Institutional Trade Volume: .16M
Avg Institutional Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $8.44M
Avg Closing Trade (30 D): $28.85M
Avg Closing Trade (90 D): $34.67M
Avg Closing Volume: 346.32K
 
News
Sep 30, 2026 @ 12:45 PM
Exelixis (EXEL) is a Top-Ranked Growth Stock: Shou...
Source: Na
Sep 30, 2026 @ 8:58 AM
Bone Metastasis in Solid Tumors Market Insights, E...
Source: Researchandmarkets.Com
Jul 29, 2026 @ 10:56 PM
Kuehn Law Encourages Investors of EXELIXIS, Inc. t...
Source: Kuehn Law, Pllc
Jun 10, 2026 @ 5:00 PM
Metastatic Prostate Cancer Market Set for Robust G...
Source: Delveinsight
May 15, 2026 @ 11:30 PM
Prediction: This Stock Could Double By 2031
Source: Prosper Junior Bakiny
Financials
  TTM Q2 2027 Q1 2027
Basic EPS $.85 $.81
Diluted EPS $.82 $.79
Revenue $628.69M $610.81M
Gross Profit $608.03M $590.86M
Net Income / Loss $212.05M $210.47M
Operating Income / Loss $248.41M $251.34M
Cost of Revenue $20.66M $19.95M
Net Cash Flow $55.3M $-256.34M
PE Ratio